Page 136 - Genentech News Today

The European Commission has granted conditional marketing authorization to glofitamab for fixed-duration administration in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic treatment.

Basel, 11 July 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has granted conditional marketing authorisation for…

/PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation,...

– Former FDA Associate Commissioner of External Affairs brings nearly 20 years of communications, patient advocacy and public affairs experience across government, public and private sectors –MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery...

This study reports the results of 3 randomized, double-masked, placebo-controlled substudies of abatacept, cenicriviroc, and infliximab plus standard care for C

/PRNewswire/ -- DelveInsights KRAS Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS...

Noninferiority versus monthly injections maintained at 2 years, as recall remains in effect

The South San Francisco Chamber of Commerce has named a new executive team to lead the business community out of the pandemic, becoming the first all-minority leadership team in the

MILL HALL — The Keystone Central School District Board of Directors is continuing its discussion surrounding safety in its facilities — with the potentia

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity.